DLX-2323 Phase 1 Trial Data on Anti-Drug Antibody Impact on Pharmacokinetics

A dataset from a Phase 1 clinical trial of DLX-2323, a humanized antibody targeting IL-1β. It includes results from ADA-sensitive pharmacokinetic and pharmacodynamic assays measuring drug concentration and activity in healthy participants. The dataset was authored by Devangi Mehta and uploaded to figshare in May 2026.

Use Cases

• Modeling drug clearance and volume of distribution based on pre-existing ADA signal-to-noise magnitude
• Analyzing the correlation between ADA magnitude and pharmacodynamic activity variability
• Comparing ADA-sensitive PK/PD assay results with standalone neutralizing antibody assay outcomes

Strengths

• Includes data from ADA-sensitive assays providing clinically meaningful PK/PD information
• Contains findings on pre-existing ADA observed in one-third of participants

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare

Collection Method

Data collected from a Phase 1 clinical trial evaluation.

Freshness

Last updated 2026-05-05 13:42:43; freshness should be verified